Of the women who showed lesion responses at week 52, 5 out of 10 also cleared their HPV16 infection compared with only 1 out of 6 non-responders; however, this did not reach statistical significance.
← all excerpts
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.
1
—
—